Adam D. Highley, MD

Department

• Medicine

Position

• Assistant Professor

Articles

• , 164, A1596-A1597
• , 51
• , 4, A1904
• , 156, A1041
• , 11;8, 3270-3275
• , 2019 44;7, HS2-HS7
• , 47, 528

Presentations

Grant Funding Received

• Sub Investigator - GSK COPD CTT116855: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, al administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease
• Sub Investigator - Insmed MAC: A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment
• Sub Investigator - Janssen: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)
• Sub Investigator: CXA-NP-11-04: A Prospecteive, Randomized, Double Blind, Multicenter, Phase III Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared with Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia.
• Sub Investigator AstraZeneca: Double-Blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinuim Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD)
• Sub Investigator - AstraZeneca: A Randomized, Double-blind, double dummy, chronic dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to evaluate the efficacy and safety of 3 doses of Benralizumab in patients with moderate to very severe chronic obstructive pulmonary disease with a history of COPD exacerbations

• Internal Medicine Teaching Award, Division, 2020
• Internal Medicine Teaching Award, Division, 2019